Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.53 |
| ▸ | PPARA | Q07869 | 13/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855692 | 0.86 | KDR (0.56) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL5858038 | 0.85 | PPARG (0.53) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL5855712 | 0.77 | PPARG (0.55) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL4037331 | 0.76 | KDM4E (0.69) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL1874497 | 0.75 | KDM4E (0.60) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL979145 | 0.73 | KDM4E (0.65) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL4031706 | 0.73 | KDR (0.57) | PPARGPPARAKDM4EKDRHPGD | |
| SCHEMBL31180903 | 0.72 | PPARG (0.52) | PPARGPPARAKDM4EKDRFFAR1 | |
| SCHEMBL8799936 | 0.72 | KDM4E (0.46) | PPARGPPARAKDM4ENPC1RAB9A | |
| SCHEMBL8551321 | 0.72 | KDM4E (0.46) | PPARGPPARAKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | PPARG 393/4885PPARA 464/4885KDM4E 1600/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | PPARG 603/4885PPARA 579/4885KDM4E 1141/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARG 701/4885PPARA 660/4885KDM4E 1321/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARG 701/4885PPARA 660/4885KDM4E 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.